XILIO THERAPEUTICS, INC.
1 day chart
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built its geographically precise solutions platform to rapidly engineer molecules, including cytokines and other biologics. Its tumor-activated, clinical-stage product candidates are XTX202, an interleukin 2 (IL-2), therapy, XTX301, an interleukin 12 (IL-12), therapy and XTX101. Its XTX101 is designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment and improve upon the therapeutic index of existing anti-CTLA-4 therapies. Its XTX101 in an ongoing Phase I clinical trial in patients with advanced solid tumors. XTX202 is an investigational tumor-activated beta-gamma biased (non-alpha), engineered IL-2 molecule designed to potently stimulate CD8+ effector T cells and NK cells without concomitant stimulation of regulatory T cells.
Buy US stocks in Australia starting with XLO. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in XLO
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.